NextCure, Inc. (NXTC)

NextCure Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	-	22.38
Revenue Growth (YoY)	-	-	-	-	252.58%
Cost of Revenue	-	-	-	-	46.55
Gross Profit	-	-	-	-	-24.18
Selling, General & Admin	15.72	19.71	21.71	20.57	17.05
Research & Development	41.49	47.93	54.2	50.19	-
Operating Expenses	57.21	67.64	75.91	70.77	17.05
Operating Income	-57.21	-67.64	-75.91	-70.77	-41.23
Interest Expense	-	-	-	-0.08	-0.18
Interest & Investment Income	4.09	4.91	1.17	1.4	4.74
EBT Excluding Unusual Items	-53.11	-62.72	-74.74	-69.45	-36.67
Merger & Restructuring Charges	-2.54	-	-	-	-
Gain (Loss) on Sale of Investments	-	-	0.01	0.06	0.07
Pretax Income	-55.65	-62.72	-74.73	-69.39	-36.6
Net Income	-55.65	-62.72	-74.73	-69.39	-36.6
Net Income to Common	-55.65	-62.72	-74.73	-69.39	-36.6
Shares Outstanding (Basic)	28	28	28	28	28
Shares Outstanding (Diluted)	28	28	28	28	28
Shares Change (YoY)	0.46%	0.33%	0.46%	0.30%	75.41%
EPS (Basic)	-1.99	-2.25	-2.69	-2.51	-1.33
EPS (Diluted)	-1.99	-2.25	-2.69	-2.51	-1.33
Free Cash Flow	-41.28	-53.79	-56	-59.64	-52.09
Free Cash Flow Per Share	-1.48	-1.93	-2.02	-2.16	-1.89
Gross Margin	-	-	-	-	-108.03%
Operating Margin	-	-	-	-	-184.22%
Profit Margin	-	-	-	-	-163.57%
Free Cash Flow Margin	-	-	-	-	-232.75%
EBITDA	-54.34	-63.95	-71.79	-66.59	-37.81
EBITDA Margin	-	-	-	-	-168.97%
D&A For EBITDA	2.87	3.68	4.12	4.18	3.41
EBIT	-57.21	-67.64	-75.91	-70.77	-41.23
EBIT Margin	-	-	-	-	-184.22%

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q